

Ego's Recommended Reading

Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB. Aging of microstructural compartments in human compact bone. *J Bone Miner Res.* 2003 Jun;18(6):1012-9.

Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F. High bone mass in mice expressing a mutant LRP5 gene. *J Bone Miner Res.* 2003 Jun;18(6):960-74.

Yanfei L. Ma, Henry U. Bryant, Qingqiang Zeng, Allen Schmidt, Jennifer Hoover, Harlan W. Cole, Wei Yao, Webster S. S. Jee and Masahiko Sato. New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats *Endocrinology* 2003;144: 2008-2015

Bonyadi M. Waldman SD. Liu D. Aubin JE. Grynepas MD. Stanford WL. Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. *Proceedings of the National Academy of Sciences of the United States of America.* 100(10):5840-5, 2003 May 13.

Ahlborg HG et al Bone loss and bone size after menopause. *New Engl J Medicine* 2003;349:327-34

Nobuchika Yamamoto, Fumihiko Sakai, Shigeyuki Kon, Junko Morimoto, Chiemi Kimura, Harumi Yamazaki, Ikuko Okazaki, Nobuo Seki, Takashi Fujii, and Toshimitsu Uede. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. *J. Clin. Invest.* 2003 Jul 15; 112 (2) : 181-188. See also Ellen M. Gravalles. Osteopontin: a bridge between bone and the immune system. *J. Clin. Invest.* 2003 Jul 15; 112 (2) : 147-149.

Hirota Kawano, Takashi Sato, Takashi Yamada, Takahiro Matsumoto, Keisuke Sekine, Tomoyuki Watanabe, Takashi Nakamura, Toru Fukuda, Kimihiro Yoshimura, Tatsuya Yoshizawa, Ken-ichi Aihara, Yoko Yamamoto, Yuko Nakamichi, Daniel Metzger, Pierre Chambon, Kozo Nakamura, Hiroshi Kawaguchi, and Shigeaki Kato. Suppressive function of androgen receptor in bone resorption. *PNAS* 2003 Aug 5; 100 (16) : 9416-9421.

Roberta Faccio, Deborah V. Novack, Alberta Zallone, F. Patrick Ross, and Steven L. Teitelbaum. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by $\beta 3$ integrin. *J. Cell Biol.* 2003 Aug 4; 162 (3) : 499-509.

Ming Teng, Myles Wolf, Edmund Lowrie, Norma Ofsthun, J. Michael Lazarus, and Ravi Thadhani. Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. *N. Engl. J. Med.* 2003 Jul 31; 349 (5) : 446-456.

Oreffo RO, Lashbrooke B, Roach HI, Clarke NM, Cooper C. Maternal protein deficiency affects mesenchymal stem cell activity in the developing offspring. *Bone.* 2003 Jul;33(1):100-7.

Boivin et al Contribution of raloxifene and calcium and vitamin D supplementation to the increase of the degree of mineralization of bone in postmenopausal women. *J Clin Endocrinol Metab* 2003 88; 4199-4205

Danova NA, Colopy SA, Radtke CL, Kalscheur VL, Markel MD, Vanderby R, McCabe RP, Escarcega AJ, Muir P. Degradation of bone structural properties by accumulation and coalescence of Microcracks. *Bone* 2003; 33:197-205.

Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor- β by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. *J Biol Chem.* 2003 Aug 27

Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P,

Nakamura K, Kawaguchi H, Kato S. Suppressive function of androgen receptor in bone resorption. *Proc Natl Acad Sci U S A*. 2003 Aug 5;100(16):9416-21

O'Brien FJ, Taylor D, Lee TC. Microcrack accumulation at different intervals during fatigue testing of compact bone. *J Biomech*. 2003 Jul;36(7):973-80.

Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause *N Engl J Med*. 2003 Jul 24;349(4):327-34.

The periosteal will have its 15 minutes of fame. Prospective studies of 15 years duration are uncommon but do they make better truth. Cortical thickness was maintained by periosteal apposition despite 15 years of endocortical resorption, now that is interesting, if it is correct.es

Safadi FF, Xu J, Smock SL, Kanaan RA, Selim AH, Odgren PR, Marks SC Jr, Owen TA, Popoff SN. Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. *J Cell Physiol*. 2003 Jul;196(1):51-62.

Khokha MK, Hsu D, Brunet LJ, Dionne MS, Harland RM. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. *Nat Genet*. 2003 Jul;34(3):303-7.

Daci E, Everts V, Torrekens S, Van Herck E, Tigchelaar-Gutter W, Bouillon R, Carmeliet G. Increased bone formation in mice lacking plasminogen activators. *J Bone Miner Res*. 2003 Jul;18(7):1167-76.

Danks JA, Ho PM, Notini AJ, Katsis F, Hoffmann P, Kemp BE, Martin TJ, Zajac JD. Identification of a parathyroid hormone in the fish *Fugu rubripes*. *J Bone Miner Res*. 2003 Jul;18(7):1326-31.

Min JK, Kim YM, Kim YM, Kim EC, Gho YS, Kang IJ, Lee SY, Kong YY, Kwon YG. Vascular endothelial growth factor up-regulates expression of receptor activator of NF- κ B (RANK) in endothelial cells: Concomitant increase of angiogenic responses to RANK ligand. *J Biol Chem*. 2003 Jul 31 [Epub ahead of print].

Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction *Journal of Clinical Investigation*. 110(10):1419-1427, 2002 Nov.

Redlich et al report the results of a beautifully designed study crossing transgenic mice that express human TNF and develop destructive arthritis with osteopetrotic, c-fos-deficient mice lacking osteoclasts. Arthritis and joint destruction is found without bone destruction. Could bisphosphonates become an integral part of management of inflammatory arthritis?

Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M.

Kay C, Seif M, Buckley H. Oestrogen therapy for prevention of reinfarction in postmenopausal

women: a randomised placebo controlled trial *Lancet*. 360(9350):2001-2008, 2002 Dec 21.

Roy DK, Pye SR, Lunt M, O'Neill TW, Todd C, Raspe H, Reeve J, Silman AJ. Bone 2002 Dec;31(6):712-7. Falls explain between-center differences in the incidence of limb fracture across Europe.

The relationship between bone density and incident vertebral fracture in men and women. The European Prospective Osteoporosis Study (EPOS) Group. *J Bone Miner Res* 2002 Dec;17(12):2214-21

Van Pottelbergh I, Goemaere S, Zmierzak H, De Bacquer D, Kaufman JM. Deficient acquisition of bone during maturation underlies idiopathic osteoporosis in men: evidence from a three-generation family study. *J Bone Miner Res* 2003 Feb;18(2):303-11

Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. *J Bone Miner Res* 2003 Jan;18(1):18-23

Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. *Osteoporos Int* 2003 Jan;14(1):77-81

van der Eerden BCJ, Emons J, Ahmed S, van Essen HW, Lowik CWGM, Wit JM, Karperien M. Evidence for genomic and nongenomic actions of estrogen in growth plate regulation in female and male rats at the onset of sexual maturation *Journal of Endocrinology*. 175(2):277-288, 2002 Nov.

Martin TJ. Manipulating the environment of cancer cells in bone: a novel therapeutic Approach. *Journal of Clinical Investigation*. 110(10):1399-1401, 2002

Tinetti ME. Preventing falls in elderly persons. *New England Journal of Medicine*. 348(1):42-49, 2003 Jan 2.

Khoury MJ, McCabe LL, McCabe ERB. Genomic medicine - Population screening in the age of genomic medicine. *New England Journal of Medicine*. 348(1):50-58, 2003 Jan 2.

Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7

uncouples bone formation from bone resorption during estrogen deficiency. *Journal of Clinical*

Investigation. 110(11):1643-1650, 2002 Dec.

Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. *Journal of Clinical Investigation*. 110(12):1849-1857, 2002 Dec.

Qiu S, Rao DS, Palnitkar S, Parfitt AM. Relationships between osteocyte density and bone formation rate in human cancellous bone. *Bone* 2002 Dec;31(6):709-11

Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. *Journal of Endocrinology*. 175(2):405-415, 2002

Bischoff HA, Stahelin HB, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, Begerow B, Lew RA, Conzelmann M. *J Bone Miner Res* 2003 Feb;18(2):343-51 Effects of vitamin D and calcium supplementation on falls: a randomised controlled trial.

Hui SL, Dimeglio LA, Longcope C, Peacock M, McClintock R, Perkins AJ, Johnston CC Jr. Difference in bone mass between black and white American children: attributable to body build, sex hormone levels, or bone turnover? *J Clin Endocrinol Metab* 2003 Feb;88(2):642-9

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. The Risedronate Phase III Research Group. *Osteoporos Int* 2002 Dec;13(12):971-9

Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. *Osteoporos Int* 2002 Dec;13(12):925-31

Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. *Osteoporos Int* 2003 Jan;14(1):2-12